G
Gary J. Miller
Researcher at Anschutz Medical Campus
Publications - 97
Citations - 12888
Gary J. Miller is an academic researcher from Anschutz Medical Campus. The author has contributed to research in topics: Prostate cancer & Prostate. The author has an hindex of 44, co-authored 97 publications receiving 12436 citations. Previous affiliations of Gary J. Miller include University of Colorado Hospital & University of Colorado Denver.
Papers
More filters
Journal ArticleDOI
The Influence of Finasteride on the Development of Prostate Cancer
Ian M. Thompson,Phyllis J. Goodman,Catherine M. Tangen,M. Scott Lucia,Gary J. Miller,Leslie G. Ford,Michael M. Lieber,R. Duane Cespedes,JN Atkins,Scott M. Lippman,Susie M. Carlin,Anne Ryan,Connie M. Szczepanek,John Crowley,Charles A. Coltman +14 more
TL;DR: Finasteride prevents or delays the appearance of prostate cancer, but this possible benefit and a reduced risk of urinary problems must be weighed against sexual side effects and the increased risk of high-grade prostate cancer.
Journal ArticleDOI
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
John D. McConnell,Claus G. Roehrborn,Oliver Bautista,Gerald L. Andriole,Christopher M. Dixon,John W. Kusek,Herbert Lepor,Kevin T. McVary,Leroy M. Nyberg,Harry Clarke,E. David Crawford,Ananias C. Diokno,John P. Foley,Harris E. Foster,Stephen C. Jacobs,Steven A. Kaplan,Karl J. Kreder,Michael M. Lieber,M. Scott Lucia,Gary J. Miller,Mani Menon,Douglas F. Milam,Joe W. Ramsdell,Noah S. Schenkman,Kevin M. Slawin,Joseph A. Smith +25 more
TL;DR: Long-term combination therapy with doxazosin and finasteride was safe and reduced the risk of overall clinical progression of benign prostatic hyperplasia significantly more than did treatment with either drug alone.
Journal ArticleDOI
Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial
Ian M. Thompson,Catherine M. Tangen,Jorge Paradelo,M. Scott Lucia,Gary J. Miller,Dean A. Troyer,Edward M. Messing,Jeffrey D. Forman,Joseph L. Chin,Gregory P. Swanson,Edith D. Canby-Hagino,E. David Crawford +11 more
TL;DR: Adjuvant radiotherapy after radical prostatectomy for a man with pT3N0M0 prostate cancer significantly reduces the risk of metastasis and increases survival.
Journal ArticleDOI
Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial.
Ian M. Thompson,Catherine M. Tangen,Jorge Paradelo,M. Scott Lucia,Gary J. Miller,Dean A. Troyer,Edward M. Messing,Jeffrey D. Forman,Joseph L. Chin,Gregory P. Swanson,Edith Canby-Hagino,E. David Crawford +11 more
TL;DR: In men who had undergone radical prostatectomy for pathologically advanced prostate cancer, adjuvant radiotherapy resulted in significantly reduced risk of PSA relapse and disease recurrence, although the improvements in metastasis-free survival and overall survival were not statistically significant.
Journal ArticleDOI
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer
Mario A. Eisenberger,Brent A. Blumenstein,E. David Crawford,Gary J. Miller,David G. McLeod,Patrick J. Loehrer,George Wilding,Kathy Sears,Daniel J. Culkin,Ian M. Thompson,Anton J. Bueschen,Bruce A. Lowe +11 more
TL;DR: The addition of flutamide to bilateral orchiectomy does not result in a clinically meaningful improvement in survival among patients with metastatic prostate cancer.